Clinical Trial News Archive - April 2022
April 1, 2022
- Merck and Ridgeback to Present Data Demonstrating That Treatment With Lagevrio (molnupiravir) Was Associated With More Rapid Elimination of Infectious SARS-CoV-2 Than Placebo
- Asceneuron Publishes Pioneering Preclinical Efficacy Data on its Novel Clinical Molecule ASN90 in Both Alzheimer's and Parkinson's Disease Models
- Altimmune Announces Initiation Of 48-Week Phase 2 MOMENTUM Trial Of Pemvidutide In Obesity
April 2, 2022
April 3, 2022
April 4, 2022
- BeyoND Phase 2b Data Indicates ND0612 Has a Positive Long-Term Safety Profile for People with Parkinson's Disease
- Theravance Biopharma, Inc. Announces Results from Study 0170, a Second Phase 3 Study of Ampreloxetine, in Patients with Symptomatic Neurogenic Orthostatic Hypotension (nOH)
- World Health Organization Updated Emergency Use Listing Recommends Johnson & Johnson COVID-19 Vaccine for Booster Use
- AZD8233 Reduced Low-Density Lipoprotein Cholesterol Levels by 73% in Patients with High-Risk Hypercholesterolemia in ETESIAN Phase IIb Trial
April 5, 2022
- Iovance Biotherapeutics Announces Regulatory and Clinical Updates for Lifileucel In Melanoma
- Study Demonstrates that Cardiologs' AI Dramatically Reduces Inconclusive Apple Watch ECGs
- FDA Updates Sotrovimab Emergency Use Authorization
April 6, 2022
April 7, 2022
- ABIONYX Pharma Reports Positive Interim Results from Phase 2a Clinical Trial Evaluating CER-001 in the Treatment of Septic Patients at High Risk of Developing Acute Kidney Injury
- Henlius' Serplulimab Granted Orphan-Drug Designation in the United States for Small Cell Lung Cancer
- Proof Diagnostics Submits Request For Emergency Use Authorization Seeking First Approval Of Crispr-Based Molecular Point-Of-Care COVID-19 Test
April 8, 2022
- Some Arthritis Drugs May Reduce Alzheimer’s and Related Dementias Risk in Those with Heart Disease
- U.S. FDA Approves Extended Shelf Life up to 11 Months for the Johnson & Johnson COVID-19 Vaccine
- Indivior Publishes Modeling Data Showing Buprenorphine May Mitigate Fentanyl-Induced Respiratory Depression in Chronic Opioid Users
April 11, 2022
- Moderna Announces First Participants Dosed in Phase 1/2 Study with mRNA-1020 and mRNA-1030 Seasonal Influenza Vaccine Candidates
- FDA Lifts Partial Clinical Hold on MDS and AML Magrolimab Studies
- Veru’s Novel COVID-19 Drug Candidate Sabizabulin Reduces Deaths by 55% in Hospitalized Patients in Interim Analysis of Phase 3 Study; Independent Data Monitoring Committee Halts Study Early for Overwhelming Efficacy
- Lilly's Lebrikizumab Combined with Topical Corticosteroids Showed Significant Improvements in Disease Severity for Atopic Dermatitis
- New Clinical Trial on Safety and Efficacy of ImmunoSEB and ProbioSEB CSC3 Combination for Long-COVID Fatigue
- Veru’s Novel COVID-19 Drug Candidate Reduces Deaths by 55% in Hospitalized Patients in Interim Analysis of Phase 3 Study; Independent Data Monitoring Committee Halts Study Early for Overwhelming Efficacy
April 12, 2022
April 13, 2022
April 14, 2022
- Pfizer and BioNTech Announce Data Demonstrating High Immune Response Following a Booster Dose of their COVID-19 Vaccine in Children 5 Through 11 Years of Age
- Positive Phase 1/2 Study Results of Rilzabrutinib in People with Immune Thrombocytopenia Published in The New England Journal of Medicine
- U.S. FDA Extends Review of Biologics License Application for REGEN-COV® (casirivimab and imdevimab) for Treatment and Prophylaxis of COVID-19
- Merck Announces U.S. FDA has Granted Breakthrough Therapy Designation for V116, the Company’s Investigational 21-Valent Pneumococcal Conjugate Vaccine, for the Prevention of Invasive Pneumococcal Disease and Pneumococcal Pneumonia in Adults
- Micreos Pharmaceuticals announces success of its XZ.700 technology in selectively eliminating Staphylococcus aureus pathogen without triggering resistance
- Coherus and Junshi Biosciences Announce PD-1 Inhibitor Toripalimab Granted Orphan Drug Designation for Small Cell Lung Cancer in the United States
April 15, 2022
- TG Therapeutics Announces Voluntary Withdrawal of the BLA/sNDA for U2 to Treat Patients with CLL and SLL
- FDA Authorizes First COVID-19 Diagnostic Test Using Breath Samples
April 18, 2022
- Nektar and Bristol Myers Squibb Announce Update on Clinical Development Program for BEMPEG in Combination with Opdivo
- Amgen Announces Positive Top-Line Results From Phase 3 Study of ABP 654, Biosimilar Candidate to Stelara® (ustekinumab)
April 19, 2022
- Teva and MedinCell Receive Complete Response Letter for TV-46000/mdc-IRM
- Moderna Announces Clinical Update on Bivalent COVID-19 Booster Platform
April 20, 2022
- Initial Results from Novavax' COVID-19-Influenza Vaccine Trial are First to Show Feasibility of Combination Vaccine
- Initial Results from Novavax' COVID-19-Influenza Vaccine Trial are First to Show Feasibility of Combination Vaccine
- Evusheld Significantly Protected Against Symptomatic COVID-19 for at Least Six Months in PROVENT Phase III Trial in High-Risk Populations
April 21, 2022
- NRx Pharmaceuticals Files New Breakthrough Therapy Designation Request for Zyesami (aviptadil) in Subgroup of Patients with Critical COVID-19 with Respiratory Failure that were also treated with Remdesivir and continued to progress
- Orasis Pharmaceuticals Announces Positive Phase 3 Topline Results of Novel Eye Drop Candidate, CSF-1, for the Treatment of Presbyopia
- Orasis Pharmaceuticals Announces Positive Phase 3 Topline Results of Novel Eye Drop Candidate, CSF-1, for the Treatment of Presbyopia
April 22, 2022
- Isofol announces start of study data analysis of phase III AGENT study in advanced metastatic colorectal cancer
- Novavax Announces Initiation of COVID-19 Vaccine Booster Study in Adolescents in Phase 3 PREVENT-19 Trial
April 24, 2022
April 25, 2022
- FDA Approves First COVID-19 Treatment for Young Children
- Tremelimumab Accepted Under Priority Review in the US for Patients with Unresectable Liver Cancer in Combination with Imfinzi
April 26, 2022
- Citius Pharmaceuticals Enrolls First Patient in Phase 2b Study of Halo-Lido for the Prescription Treatment of Hemorrhoids
- Pfizer and BioNTech Submit Application for U.S. Emergency Use Authorization for a COVID-19 Vaccine Booster Dose in Children 5 Through 11 Years of Age
- Valneva and Pfizer Report Positive Phase 2 Pediatric Data for Lyme Disease Vaccine Candidate
April 27, 2022
- Allogene Therapeutics Receives FDA Orphan-Drug Designation for ALLO-605, its First TurboCAR™ T Cell Product Candidate, for the Treatment of Multiple Myeloma
- BioCorRx Begins Recruitment for Clinical Trial of BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder
- Modeling Published in Neurology and Therapy Suggests that Lecanemab Could Delay Progression to Alzheimer's Dementia by Several Years
- Enhertu Granted Breakthrough Therapy Designation in U.S. for Patients with HER2 Low Metastatic Breast Cancer
April 28, 2022
April 29, 2022
- Lyra Therapeutics Presents Positive Data from LANTERN Phase 2 Study of LYR-210 for Treatment of Chronic Rhinosinusitis
- Related Biological Products Advisory Committee Review of Novavax' COVID-19 Vaccine
- Pfizer Shares Top-Line Results from Phase 2/3 EPIC-PEP Study of Paxlovid for Post-Exposure Prophylactic Use
Clinical trial results archive
- 2024
- January, February, March, April, May, June, July, August, September, October, November
- 2023
- January, February, March, April, May, June, July, August, September, October, November, December
- 2022
- January, February, March, April, May, June, July, August, September, October, November, December
- 2021
- January, February, March, April, May, June, July, August, September, October, November, December
- 2020
- January, February, March, April, May, June, July, August, September, October, November, December
- 2019
- January, February, March, April, May, June, July, August, September, October, November, December
- 2018
- January, February, March, April, May, June, July, August, September, October, November, December
- 2017
- May, June, July, August, September, October, November, December
- 2016
- October
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.